Ally Bridge Group is a global healthcare investment management firm focused on high-impact life science innovation across private and public markets. Founded in 2013 by Frank Yu, the firm manages assets from offices in New York and Hong Kong.
39% of their portfolio is in Healthcare. Average disclosed round size is $107.1M (across 100 rounds with reported amounts).
Portfolio
73
Fund Size
—
Top Stage
Bridge
Last 12 Mo
5
Team
AL
Andrew Lam, PharmD
Managing Director, Head of Biotech
CW
Charles Wong, CPA
Managing Director, Chief Operating Officer, Chief Financial Officer
EY
Emma Yang
Director of Legal
CS
Carlos Solorzano, PhD
Principal
JW
Jonathan Wang, CFA, CPA
Vice President
KC
Kelly Cheng, CPA
Vice President
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
116 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Solve Therapeutics | Bridge | $120M | Sep 2026 |
 Calyxo | Series F | $40M | Apr 2026 |
 Ovid Therapeutics Inc. | Series B | $60M | Mar 2026 |
| Solve Therapeutics | Unknown | $120M | Jan 2026 |
 Climb Bio | Unknown | $110M | Jan 2026 |
 First Tracks | Unknown | $80M | Jan 2026 |
| Ovid Therapeutics Inc. | Bridge | $60M | Jan 2026 |
 Biobeat | Series B | $50M | Dec 2025 |
| Solve Therapeutics | Series D | $120M | Nov 2025 |
 Galvanize Therapeutics | Series C | $100M | Sep 2025 |
 Galvanize | Bridge | — | Sep 2025 |
 Cardiac Dimensions | Series E | $53M | Mar 2025 |
 Arbor Biotechnologies | Series C | $73.9M | Mar 2025 |
 VitalConnect | Series F | $30M | Jan 2025 |
 Lexeo | Unknown | $80M | Jan 2025 |
| Cardiac Dimensions | Series E | $53M | Jan 2025 |
 INSIGHTEC | Growth | $150M | Jun 2024 |
 Transcarent | Series D | $126M | May 2024 |
 Endeavor Biomedicines | Unknown | $132.5M | Apr 2024 |
 Alumis | Series C | $259M | Mar 2024 |
 ProfoundBio | Series B | $112M | Feb 2024 |
 Transcarent | Series D | $126M | Jan 2024 |
 Kestra Medical Technologies | Unknown | $196M | Jan 2024 |
| INSIGHTEC | Growth | $150M | Jan 2024 |
| AAeglea Biotherapeutics | Bridge | — | Aug 2023 |
Page 1 of 5
Top Co-Investors
T. Rowe Price19 shared
Sofinnova Partners17 shared
Venrock14 shared
Perceptive Advisors13 shared
Cormorant Asset Management12 shared
OrbiMed12 shared
Catalio Capital Management11 shared
Norwest Venture Partners10 shared
RA Capital Management9 shared
Deerfield9 shared
EDBI7 shared
Hillhouse Investment7 shared
Gilmartin Capital7 shared
Surveyor Capital7 shared
Omega Funds7 shared
Bain Capital Life Sciences7 shared
Elevage Medical Technologies6 shared
Fidelity Investments6 shared
Last updated: 20 October 2026